Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 706321 plus ustekinumab induction in moderately to severely active Crohn's disease
NL-OMON53423Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing BI 706321 + ustekinumab with Placebo + ustekinumab (2 arms). Primary endpoint: Absolute change from baseline in SES-CD at week 12. Started Feb 2024; status: completed.
02
Drugs
bi 706321ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON53423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53423.